Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 18, 2022 09:15 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Secures Worldwide Rights to G4-Selective Transcription Inhibitors from University College London to Develop as Cancer Therapeutics

Preclinical Therapeutic Program to Be Initially Focused on Pancreatic Cancer CARLSBAD, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology...